InMed Pharmaceuticals (INM) Retained Earnings (2020 - 2026)

InMed Pharmaceuticals has reported Retained Earnings for 7 years, with the latest figure at -$124.0 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 96546.27% year-over-year to -$124.0 million; the trailing twelve-month figure through Mar 2026 stood at -$124.0 million (down 96546.27% YoY), and the FY2025 full-year result was $128569.0, changed 0.0% from the prior year.
• Retained Earnings for Q1 2026 stood at -$124.0 million, down from -$121.0 million in the prior quarter.
• The five-year high for Retained Earnings was $128569.0 in Q1 2022, with the low at -$124.0 million in Q1 2026.
• Historically, Retained Earnings has averaged -$57.7 million across 5 years, with a median of -$97.0 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 100.18% — and 2026, when it sank 96546.27%.
• InMed Pharmaceuticals' Retained Earnings stood at -$99.1 million in 2022, then slipped by 6.4% to -$105.4 million in 2023, then dropped by 7.5% to -$113.3 million in 2024, then declined by 6.8% to -$121.0 million in 2025, then slipped by 2.48% to -$124.0 million in 2026.
• The last three Retained Earnings figures came in at -$124.0 million (Q1 2026), -$121.0 million (Q4 2025), and -$119.0 million (Q3 2025), per Business Quant data.